Trial Profile
A Treatment Protocol for Patients Continuing From SU011248 Protocols.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Oct 2012
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 05 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Sep 2012 Planned end date changed from 1 Feb 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.
- 23 Sep 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.